Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$106.435
Market cap
$269.79B
P/E Ratio
19.67
Dividend/share
$3.08
EPS
$5.41
Enterprise value
$296.28B
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the
Highlights
The P/E is 92% lower than the last 4 quarters average of 250.9 and 73% lower than the 5-year quarterly average of 73.4
MRK's quick ratio is up by 29% since the previous quarter and by 19% year-on-year
MRK's debt is up by 10% since the previous quarter and by 2.4% year-on-year
Key stats
What are the main financial stats of MRK
Market
Valuations
Earnings
Shares outstanding
2.53B
Market cap
$269.79B
Enterprise value
$296.28B
Price to earnings (P/E)
19.67
Price to book (P/B)
6.19
Price to sales (P/S)
4.32
EV/EBIT
17.98
EV/EBITDA
14.4
EV/Sales
4.74
Revenue
$62.48B
EBIT
$16.47B
EBITDA
$20.57B
Free cash flow
$13.15B
Per share
Balance sheet
Liquidity
EPS
$5.41
Free cash flow per share
$5.19
Book value per share
$17.21
Revenue per share
$24.66
TBVPS
$29.39
Total assets
$112.63B
Total liabilities
$68.98B
Debt
$37.79B
Equity
$43.58B
Working capital
$12.15B
Debt to equity
0.87
Current ratio
1.47
Quick ratio
0.88
Net debt/EBITDA
1.29
Margins
Efficiency
Dividend
EBITDA margin
32.9%
Gross margin
75.3%
Net margin
22%
Operating margin
24.7%
Return on assets
12.7%
Return on equity
33.8%
Return on invested capital
23.1%
Return on capital employed
19%
Return on sales
26.4%
Dividend yield
2.89%
DPS
$3.08
Payout ratio
56.9%
MRK stock price
How has the Merck stock price performed over time
Intraday
0.09%
1 week
-4.57%
1 month
-9.16%
1 year
3.67%
YTD
-2.37%
QTD
-6.27%
Financial performance
How have Merck's revenue and profit performed over time
Revenue
$62.48B
Gross profit
$47.02B
Operating income
$15.46B
Net income
$13.74B
Gross margin
75.3%
Net margin
22%
Merck's operating income has soared by 157% YoY
Merck's operating margin has surged by 140% YoY
The gross profit has grown by 11% year-on-year and by 3% since the previous quarter
The revenue has grown by 7% YoY
Growth
What is Merck's growth rate over time
Valuation
What is Merck stock price valuation
P/E
19.67
P/B
6.19
P/S
4.32
EV/EBIT
17.98
EV/EBITDA
14.4
EV/Sales
4.74
The P/E is 92% lower than the last 4 quarters average of 250.9 and 73% lower than the 5-year quarterly average of 73.4
The price to book (P/B) is 15% lower than the last 4 quarters average of 7.3 and 6% lower than the 5-year quarterly average of 6.6
Merck's equity has increased by 13% YoY and by 8% from the previous quarter
MRK's P/S is 12% below its last 4 quarters average of 4.9 and 8% below its 5-year quarterly average of 4.7
The revenue has grown by 7% YoY
Efficiency
How efficient is Merck business performance
The ROS has soared by 140% YoY
The ROIC has soared by 133% YoY
Dividends
What is MRK's dividend history
DPS
$3.08
Dividend yield
2.89%
Payout ratio
56.9%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Merck financials performed over time
The total assets is 63% more than the total liabilities
MRK's quick ratio is up by 29% since the previous quarter and by 19% year-on-year
The current ratio has grown by 18% from the previous quarter and by 15% YoY
MRK's debt is 13% smaller than its equity
Merck's equity has increased by 13% YoY and by 8% from the previous quarter
MRK's debt is up by 10% since the previous quarter and by 2.4% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.